Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34190581)

  • 1. Immunotherapy for cholangiocarcinoma: a 2021 update.
    Charalampakis N; Papageorgiou G; Tsakatikas S; Fioretzaki R; Kole C; Kykalos S; Tolia M; Schizas D
    Immunotherapy; 2021 Sep; 13(13):1113-1134. PubMed ID: 34190581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
    Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
    Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholangiocarcinoma in the Era of Immunotherapy.
    Manthopoulou E; Ramai D; Dhar J; Samanta J; Ioannou A; Lusina E; Sacco R; Facciorusso A
    Vaccines (Basel); 2023 Jun; 11(6):. PubMed ID: 37376451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma.
    Sadeghi S; Bejjani A; Finn RS
    Surg Oncol Clin N Am; 2019 Oct; 28(4):695-715. PubMed ID: 31472914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma.
    Chen F; Sheng J; Li X; Gao Z; Zhao S; Hu L; Chen M; Fei J; Song Z
    Biomed Pharmacother; 2024 Jun; 175():116659. PubMed ID: 38692063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapies for intrahepatic cholangiocarcinoma.
    Kelley RK; Bridgewater J; Gores GJ; Zhu AX
    J Hepatol; 2020 Feb; 72(2):353-363. PubMed ID: 31954497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers.
    Chen R; Zheng D; Li Q; Xu S; Ye C; Jiang Q; Yan F; Jia Y; Zhang X; Ruan J
    Cancer Lett; 2022 Oct; 546():215853. PubMed ID: 35921970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitors and combinations with other agents in cholangiocarcinoma.
    Skouteris N; Papageorgiou G; Fioretzaki R; Schizas D; Kykalos S; Tolia M; Charalampakis N
    Immunotherapy; 2023 May; 15(7):487-502. PubMed ID: 36876442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers.
    Zhou G; Boor PPC; Bruno MJ; Sprengers D; Kwekkeboom J
    Br J Cancer; 2022 Jan; 126(1):10-23. PubMed ID: 34400801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic activity of effector T cells against cholangiocarcinoma is enhanced by self-differentiated monocyte-derived dendritic cells.
    Panya A; Thepmalee C; Sawasdee N; Sujjitjoon J; Phanthaphol N; Junking M; Wongkham S; Yenchitsomanus PT
    Cancer Immunol Immunother; 2018 Oct; 67(10):1579-1588. PubMed ID: 30056600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma.
    Høgdall D; Lewinska M; Andersen JB
    Trends Cancer; 2018 Mar; 4(3):239-255. PubMed ID: 29506673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoints and their promising prospect in cholangiocarcinoma treatment in combination with other therapeutic approaches.
    Vatankhah F; Salimi N; Khalaji A; Baradaran B
    Int Immunopharmacol; 2023 Jan; 114():109526. PubMed ID: 36481527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases.
    Zhao Q; Chen Y; Du S; Yang X; Chen Y; Ji Y; Zeng Z
    Cancer Biol Ther; 2021 Mar; 22(3):175-183. PubMed ID: 33722163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications.
    Kankeu Fonkoua LA; Serrano Uson Junior PL; Mody K; Mahipal A; Borad MJ; Roberts LR
    Expert Opin Ther Targets; 2022 Jan; 26(1):79-92. PubMed ID: 35034558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts.
    Heits N; Heinze T; Bernsmeier A; Kerber J; Hauser C; Becker T; Kalthoff H; Egberts JH; Braun F
    BMC Cancer; 2016 May; 16():322. PubMed ID: 27206490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials.
    Simile MM; Bagella P; Vidili G; Spanu A; Manetti R; Seddaiu MA; Babudieri S; Madeddu G; Serra PA; Altana M; Paliogiannis P
    Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30743998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma.
    Du J; Lv X; Zhang Z; Huang Z; Zhang E
    Front Immunol; 2023; 14():1142690. PubMed ID: 36936931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging molecular therapeutic targets for cholangiocarcinoma.
    Ilyas SI; Gores GJ
    J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of Immune Checkpoint Inhibitors in the Treatment of Cholangiocarcinoma.
    Zeng FL; Chen JF
    Technol Cancer Res Treat; 2021; 20():15330338211039952. PubMed ID: 34528830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.